# CellsBin

Source: https://onco.cc/companies/cellsbin/  
OnCo record `cellsbin` (Company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

CellsBin, in Connecticut, makes instruments that find extremely rare cells in a blood sample. One is being developed to follow multiple myeloma from blood instead of repeated bone marrow biopsies.

## Summary

CellsBin, Inc. develops rare-cell detection and single-cell profiling platforms, sold for research use only. Its Scout product detects and profiles rare therapeutic cells such as CAR-T cells in circulation, and Insight is being developed for blood-based assessment of multiple myeloma, from detection and longitudinal monitoring to risk stratification. A 2026 National Cancer Institute SBIR award funds the detection and isolation of circulating myeloma cells towards a minimally invasive CLIA-certified test; the award abstract describes Insight as combining high-resolution imaging, microfluidics and machine learning.

## Fields

- Kind: Company
- Last checked: 2026-11-04
- Also known as: CellsBin, Inc.
- HQ: Branford, CT
- Type: diagnostics
- Website: https://cellsbin.com/

## Notes

- Company website and the NIH RePORTER record read on 4 November 2026. Its products are labelled research use only on the website.

## Sources

- Official website: https://cellsbin.com/
- NIH RePORTER: award 1R44CA314758-01: https://reporter.nih.gov/project-details/11409627

## Connected records

- cancers: [Multiple myeloma](https://onco.cc/cancers/multiple-myeloma/)
- fronts: [Diagnostics & Biomarkers](https://onco.cc/fronts/diagnostics/)
- technologies: [Circulating tumour cell capture](https://onco.cc/technologies/ctc-capture/)

---
JSON: https://onco.cc/api/v1/entities/cellsbin.json